Category

Archives

TEAD

Design, Synthesis, and Antitumor Activity of Erlotinib Derivatives

80 views | May 08 2022

Long-Fei Mao et al. suggested that compound 3d suppressed cancer cell proliferation through the EGFR-TK pathway. [Read the Full Post]

Combination of Ocimum sanctum extract and Levetiracetam ameliorates cognitive dysfunction and hippocampal architecture in rat model of Alzheimer's disease

261 views | Jan 03 2022

H S Nandini et al. provided evidence for use of OSE, LEV and OSE+LEV against AD and epilepsy associated with AD in Aβ induced AD animal model. [Read the Full Post]

In silico evaluation of the downstream effect of mutated glucagon is consistent with higher blood glucose homeostasis in Galliformes and Strigiformes

214 views | Oct 11 2021

Karim Mahnam et al. suggested this mutation, which leaded to stronger binding affinity of mutated glucagon to its receptor, might be a driving force for higher blood glucose homeostasis in the related birds. [Read the Full Post]

Development of LM98, a Small-Molecule TEAD Inhibitor Derived from Flufenamic Acid

248 views | Oct 10 2021

Léa Mélin et al. found that LM98 reduced the expression of CTGF and Cyr61, inhibited MDA-MB-231 breast cancer cell migration and arrested cell cycling in the S phase during cell division. [Read the Full Post]

Treatment outcomes of erlotinib plus gemcitabine as late-line chemotherapy in unresectable pancreatic cancer

525 views | Jun 16 2021

Takafumi Mie et al. found that benefits of erlotinib plus gemcitabine as late-line chemotherapy were limited, particularly with respect to PFS. [Read the Full Post]